New Jersey pharmaceutical company, Valeant Pharmaceuticals has announced the recall of one lot of the powdered antiviral drug,  Virazole® (ribavirin powder for solution) due to microbial contamination.

Respiratory syncytial virus (RSV) using indirect immunofluorescence technique/CDC
Respiratory syncytial virus (RSV) using indirect immunofluorescence technique/CDC

Virazole is packaged in 100 mL, 6 g Vial, 4-pack NDC 00187-0007-14 which is to be reconstituted with 300 mL Sterile Water for Injection or Sterile Water for Inhalation (no preservatives added) and administered only by a small particle aerosol generator (SPAG-2). The affected Virazole lot is Lot No. 340353F with an expiration date of Oct-2018. Virazole was distributed in the U.S. and Australia.

Virazole is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus (RSV). Valeant has not received reports of adverse events or injuries, related to this recall.

Inhalation of a non-sterile product with microbial contamination into the airways could increase the risk of respiratory infection. The risk is higher in patients who are immunocompromised (because of underlying disease), and are more susceptible.

Valeant Pharmaceuticals is notifying its distributors and customers by mail and is arranging for return of all recalled product of this lot. This recall only affects this lot of Virazole; all other lots are not affected and are not involved in this recall.

Customers with questions regarding this recall can contact VPNA by phone at 800-321-4576 Monday – Friday, 8am – 5pm (Eastern) or by e-mail address at [email protected]. Consumers should contact their physician or healthcare provider for questions regarding this product.

Adverse reactions or quality problems experienced with the use of this product may be reported to VPNA at 877-361-2719 or to the FDA’s MedWatch Adverse Event Reporting program as follows:

This recall is being conducted in conjunction with the U.S. Food and Drug Administration.